It all comes back to the mitochondrion
Mitochondria generate most of the cell’s usable energy, and they degrade in characteristic ways over time. That single fact is why a research area about energy and a research area about ageing keep converging on the same organelle and often the same molecules.
Three lines of work sit here. One concerns a coenzyme central to redox reactions, whose cellular levels change with age. Another concerns a peptide encoded in mitochondrial rather than nuclear DNA, which was only described relatively recently. A third concerns a short peptide studied for its interaction with a lipid specific to the inner mitochondrial membrane.
Two of those three are young fields with correspondingly thin literatures, and the compound pages say so rather than implying more certainty than exists.
Searching for peptides for energy returns those three threads mixed together with a good deal of material that belongs to none of them. Two of the compounds here are not peptides at all, which the individual files state in their opening lines rather than somewhere further down; if the naming line itself is the question, the page on what counts as a peptide draws it. The distinction is not pedantry, because the analytical questions that apply to a short synthetic sequence differ from those that apply to a coenzyme or to a small molecule such as the one described in the 5-Amino-1MQ file.
What is being investigated- Redox balance and coenzyme availability
- Peptides encoded in mitochondrial DNA
- Cardiolipin interaction at the inner membrane
- Which of these fields are genuinely young
Where this sits legally
SS-31 has been through clinical programmes under the name elamipretide. That is a different product from the research material here, with a different dossier behind it.
Compounds studied for energy
Six items spanning coenzymes, mitochondrial peptides and one enzyme inhibitor.
What the mitochondrial work has and has not shown
The measurements in this corner are made on isolated mitochondria, on cell lines and on animals of different ages: respiration rates, membrane potential, markers of oxidative damage. A marker that moves is a finding about that preparation rather than an outcome in anything larger, and the papers are generally careful about the difference even where the summaries built on them are not. One compound has travelled further than the rest: the programmes run under the name elamipretide appear among the registry entries on ClinicalTrials.gov, where the study titles, the conditions studied and the current status are listed as filed.
For the material in front of you the questions are ordinary ones. Two formats appear in this area because the routes differ, not because either is presented as better, and the page weighing a metered spray against an injected format sets out what each changes about handling. Whichever format you choose, the identity and the purity figure belong to one specific batch, and that certificate is the document worth asking for before payment.
What the energy page leaves out
No promises about ageing, and no implication that a young field is a settled one. Two of the three research threads on this page are only a few years old, and the compound files say so in the first paragraph rather than the last. Nothing here describes an outcome in a person.
The energy reading list, before you order
Four files, two of them describing fields only a few years old.
NAD+
Not a peptide at all but a coenzyme, and what it actually does in cellular metabolism.
Read CompoundMOTS-c
Encoded in mitochondrial rather than nuclear DNA. Interesting, and still thinly published.
Read CompoundSS-31
Also catalogued as elamipretide, studied for its interaction with cardiolipin.
Read CompoundEpitalon
A four-residue peptide from longevity research, with an honest look at how thin the evidence is.
ReadQuestions about energy research
Usually about what counts as a peptide and what does not.